Clinical Observation Of Bufei Anshen Prescription In The Treatment Of COPD In Stable Stage(Lung And Kidney Qi And Yin Deficiency Type) Complicated With Insomnia

Objective:To observe the TCM syndrome score,lung function,CAT score,PSQI score and ISI score of Bufei Anshen prescription in the treatment of COPD in stable stage（Lung and kidney qi and yin deficiency type）complicated with insomnia,and to evaluate its clinical efficacy and safety.Methods:From June 2020 to December 2020,68 COPD patients in stable stage（Lung and kidney qi and yin deficiency type）complicated with insomnia were randomly divided into control group and treatment group（34 cases in each group）.In the control group,33 cases were completed due to 1 case lost to follow-up,while in the treatment group,34 cases were completed due to no loss.The control group was given salmeterol and fluticasone powder inhalation（specification:50/250μg,trade name:Seretide,produced by GSK group company,imported drug registration certificate No.H20150324）,once a time,twice a day,and the content of sleep health education was explained at the same time;the treatment group was additionally given Bufei Anshen prescription,once a day,300ml water decoction,150ml warm in the morning and evening on the basis of the control group,and the course of treatment in both groups was 4 weeks.The TCM syndrome score,lung function,CAT score,PSQI score,ISI score and safety index of the two groups were recorded before and after treatment,and the data were analyzed by SPSS26.0 statistical software.Result:1.After treatment,the TCM syndrome scores of the two groups were lower than before treatment（P<0.05）,and the treatment group was better than the control group（P<0.05）.2.The total effective rate of the treatment group was 91.18%,the control group was 78.79%,the treatment group was better than the control group,the difference was statistically significant（P<0.05）.3.After treatment,there were no significant differences in FEV₁,FVC,FEV₁/FVC between the two groups（P>0.05）.4.After treatment,the CAT scores of the two groups were lower than before treatment（P<0.05）,and the treatment group was better than the control group（P<0.05）.5.After treatment,the PSQI and ISI scores of the two groups were lower than before treatment（P<0.05）,and the treatment group was better than the control group（P<0.05）.6.Before and after treatment,there was no significant change in the safety index of the two groups.Conclusion:1.Bufei Anshen prescription can improve the TCM syndromes,quality of life and sleep quality of COPD patients in stable stage（Lung and kidney qi and yin deficiency type）complicated with insomnia,and clinical safety and effectiveness.2.Bufei Anshen prescription has no obvious advantages in improving the lung function of COPD patients in stable stage（Lung and kidney qi and yin deficiency type）complicated with insomnia.